Concord Biotech's Q1 marks return to growth: consol PAT +31% YoY to ₹58 Cr, margins expand
PAT +30.96% YoY · revenue +26.23% · margins expanding
₹257.49 Cr
+26.23% YoY
₹57.7 Cr
+30.96% YoY
21.35%
+1.1pp YoY
₹5.52
Concord Biotech opened FY27 with a clear rebound after a soft FY26. Q1 consolidated revenue from operations rose 26.2% YoY to ₹257.5 Cr and net profit (attributable to owners) rose ~33% to ₹58.5 Cr (₹57.7 Cr PAT for the period after a ₹0.8 Cr non-controlling loss), against ₹204.0 Cr and ₹44.1 Cr a year ago. Margins moved the right way on both lines: operating margin expanded to ~32.0% from 30.1%, and net margin to ~22.7% from 20.2%, with the print carrying no exceptional items this quarter — so the reported growth is the underlying growth, not an optics effect. EPS was ₹5.52 vs ₹4.21.
Q1 FY-2027 vs prior quarters
The result validates management's own guidance from the Q3 FY26 concall, where it flagged FY26 as below historical averages but guided FY27 back toward historical growth with potential acceleration to a ~25% CAGR as the injectable facility, CDMO partnerships and new launches scale. A 26% YoY topline in the very first quarter sits squarely on that path. The margin recovery also aligns with management's claim that core business margins remain stable (~40% at the core level) even as new ventures carry start-up costs — the consolidated drag from those ventures is visible in the standalone-vs-consolidated gap: standalone PAT grew 43.8% YoY (to ₹61.2 Cr) versus 31% consolidated, because loss-making subsidiaries (Celliimune, acquired Apr 2, 2026; Stellon Biotech) dilute the group number. Readers seeing the higher standalone figure elsewhere should treat consolidated as the true group picture.
The stock went into the print at ₹1,420.8, up 10.5% over the past month of trading.
Management expects FY26 performance to remain below historical averages due to significant H1 challenges, but anticipates a stronger Q4 performance driven by recovering order momentum. For FY27 and beyond, the company guides for a return to historical growth, with potential acceleration towards a 25% CAGR fueled by the
— This quarter: met
Against the sequential quarter, revenue fell 21% and PAT 35% versus Q4 FY26 (₹326 Cr / ₹88.5 Cr), but Q4 is seasonally Concord's strongest quarter and that step-down is a seasonality artifact, not a deterioration — the YoY comparison is the signal here. Concurrent developments support the recovery read: Unit-II cleared Kenya and Uganda regulatory inspections in June, and the board declared the quarter alongside a final dividend (July 24 record date) and the 41st AGM. No formal quarterly guidance or published street consensus was available for this print; the FY26 base had seen consolidated revenue decline ~12%, so this quarter is the first concrete evidence of the guided turnaround taking hold. Management will detail the recovery on its August 3 earnings call.
W1
Whether the ~26% YoY revenue pace holds through FY27 to hit management's guided ~25% CAGR — Q2 is the next checkpoint
W2
Trajectory of subsidiary start-up losses (Celliimune/Stellon) closing the standalone-vs-consolidated PAT gap of ~13pp as new ventures scale
W3
OPM path back toward management's stated ~40% core-margin level as injectable facility and CDMO ramp absorbs start-up costs
Digitally-generated PDF, clean read. Source unit ₹ lakh (converted to ₹ Cr). Consolidated PBT ₹78.34 Cr includes ₹1.28 Cr share of JV profit. PAT ₹57.70 Cr is total incl. NCI; attributable to owners ₹58.53 Cr (NCI loss ₹0.83 Cr from start-up subsidiaries Celliimune/Stellon), which drives EPS ₹5.52. The ₹327.54 lakh labour-code exceptional hit sat only in the FY26 full-year column — both Q1FY27 and Q1FY26 quarterly columns are clean, so raw YoY = adjusted YoY, no restatement needed. Standalone PAT +43.8% YoY vs consolidated +31% — divergence from loss-making new subsidiaries.
Strong 26% growth, margin expansion; long-term bets ramping slower than guided
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Met Q1 revenue guidance (₹257.5 Cr delivered vs ₹257 Cr stated); delayed but now on track for injectable ramp; 40% margin timing pushed to FY28.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Q1 delivered 26% revenue growth and 31% PAT growth on broad-based API strength and pricing discipline. Long-term capacity roadmap (₹3,000 Cr via infrastructure + CDMO) is quantified and backed by execution. Key risk: injectable facility and Stellon are at 5% utilization; margin target 40% deferred to FY28, not FY27 end as originally guided.
₹257.5 Cr
Revenue · +26.2% YoY₹57.7 Cr
Reported PAT · +31% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Export revenues growing 46% YoY, broad-based across geographies
METCFO confirmed export revenues grew 46%; domestic +12%
Gross margins expanded 100 bps on pricing discipline and product mix
METGross margin 78.9%, exactly 100 bps YoY expansion confirmed
Injectable facility to meaningfully contribute to revenue and margin expansion
OVERSTATEDInjectable at 5% utilization in Q1; only in-house branded product supply; external sales expected H2 FY27+
Pricing gains from fermentation capacity scale competitive advantage
METAnkur confirmed pricing was primary driver of wallet share gains on existing products; €1.25B fermentation capacity
Will reach 40% EBITDA margin by end of FY27
MISSClarified to FY28 due to slower injectable facility ramp; 32% current, expect H2 FY27 improvement but full 40% by FY28
Earnings quality
What changed since the last call
40% EBITDA margin timing deferred
DowngradeWas guided as end-FY27 target; now clarified to FY28 due to slower injectable facility ramp from expected delays in approvals/qualifications.
Injectable facility commercialization pace
DowngradeQ1 at 5% utilization vs near-ramp expectations; external contract manufacturing to start H2 FY27 (not Q1). Facility working, but demand pull slower.
25% CAGR FY27+ guidance reaffirmed
NeutralNo change; Q1 delivered 26% growth supports trajectory. Long-term ₹3,000 Cr vision unchanged; phasing of infrastructure ramp extended by 1-2 quarters.
The Q&A
Analysts pressed on normalization vs structural gains (Parth), capacity roadmap (multiple, esp. Ritika), and timeline credibility (Alankar). Management pushed back constructively: acknowledged delays but noted facility on track post-approvals; reaffirmed long-term vision; clarified that pricing (not competitor disruption) drove wallet share. Handled tariff concern deftly (no customer feedback yet). Tone: honest about phasing, confident on fundamentals.
Normalization vs structural growth — Parth, Trinetra Asset Managers
PartialSome spillover from Q4 FY26 delays, but majority from new products and broad geographic sales expansion (US, Europe, Japan, LatAm). On track for >historical growth rates FY27.
Revenue capacity roadmap — Parth, Trinetra Asset Managers
Answered₹600-700 Cr formulations, ₹2,200-2,300 Cr APIs (injectables embedded). Injectables at nascent stage, oral solids ramping on new product launches. 5-6 years to near ₹3,000 Cr via CAGR.
Capital allocation priorities — Sajal Kapoor, Antifragile Thinking
PartialAll equally nascent and exciting. Stellon has ANDA approvals; injectables large addressable market (₹600 Cr potential), only integrated player in India; CDMO few global competitors, lengthy sales cycle. All 3 on table.
Capacity utilization view — Siddharth, CWC
AnsweredUnit 1: 80%, Unit 3: 55%, Unit 2: 25%. Anti-infectives, oncology higher growth than immuno. CDMO 1-2% of sales, intent to double-digit. Domestic formulation: Middle East tender loss (-contribution); ex-that, nephrology & critical care up double-digits.
Constant currency growth — Alok Dalal, Jefferies India
AnsweredForex 10-12% movement; net impact 3-5% to EBITDA (offset by input costs). Constant currency growth ~3-4% on top of 26%, so ~21%.
Wallet share gain drivers — Alok Dalal, Jefferies India
AnsweredPrimarily pricing, driven by fermentation capacity economies of scale. Existing products; new product conversions lower scale yet but visible. Soft aspects (fermentation partnership) secondary.
Margin target path — Alok Dalal, Jefferies India
PartialOperating leverage + renewables will drive margins better than sales growth. But need injectable & Stellon ramping to reach 40%; expect partial this year, fuller by FY28.
Injectable facility timeline — Naman Bagrecha, IIFL Capital
AnsweredCommercialized; exhibit batches on stability, filings underway. 12-15 months for emerging market approvals = next year. Focus H1 FY27 on domestic (own branded + contract). External sales Q2 H2 FY27.
Injectable facility utilization — Naman Bagrecha, IIFL Capital
Dodged5% utilization. EBITDA breakeven level unknown (promised to follow up). Couple million $ CDMO sales from one animal health project.
US tariff risk — Naman Bagrecha, IIFL Capital
DodgedNo customer feedback on concerns yet.
Capital allocation — Naman Bagrecha, IIFL Capital
PartialHistorically paid dividends; exploring organic and inorganic growth in fermentation adjacencies (peptides, veterinary, etc.). All 3 options on table.
Innovator customer engagement — Alankar, Kotak Institutional Equities
PartialAdded 2 customers last year; couple more projects progressing, expect advanced stage/closure by year-end. Leverage scale, capacity, expertise, long-standing relationships.
Injectable ramp vs expectations — Alankar, Kotak Institutional Equities
PartialDelayed couple quarters (inspections, approvals, facility qualification). Now on track as of Q1 FY27. First step critical; going forward on track.
API revenue scaling path — Ritika Agarwal, ValueQuest
AnsweredUnit 3 at 55% includes KSM manufacturing (sourced or in-house). Nystatin, fusidic acid ramps drive Unit 3 growth. Pipeline: 8-10 products, mostly anti-infectives for Unit 3 (high-value oncology in small 5K-L fermenter). Capacity utilization doesn't linearly reflect revenue (high-value oncology products).
Guidance
FY27 growth better than historical rates (>25% CAGR implied)
HighQ1 delivered 26% growth; pipeline visibility strong; export momentum +46%; new products ramping.
₹3,000 Cr revenue capacity in 5-6 years (₹2,200-2,300 Cr APIs + ₹600-700 Cr formulations)
MediumInfrastructure built/planned (fermentation capacity, injectable facility); dependent on new initiatives scaling (CDMO ramp, injectables utilization)
EBITDA margin ~40% by FY28 (deferred from end-FY27)
MediumCurrently 32% (+190 bps YoY); expects operating leverage + renewables + injectable ramp to drive. Ex-injectable/Stellon start-up costs, would be 37% in Q1.
Sustain historical margins (~40%) as injectable facility scales
MediumInjectable at 5% utilization; management confident on margin trajectory post-ramp, but dependent on contract manufacturing onboarding.
No new major capex until Unit 3 reaches 80-85% utilization
HighCurrently 55% (ex-KSM mfg); ample land (160 acres, only 20-25% used). May add capacity for fermentation adjacencies (peptides, veterinary) if dedicated requirements arise.
Risks the call surfaced
Execution risk on new ventures
HighInjectable at 5% utilization; Stellon just launched (no revenue); CDMO 1-2% of sales. Margin target 40% deferred to FY28 (from end-FY27). All 3 critical to ₹3,000 Cr vision.
Customer concentration undisclosed
MediumManagement references 'marquee customers' and 'advanced discussions with several large customers' but withholds specific customer names, wallet share, or concentration metrics.
Forex and input cost headwind
Medium10-12% dollar movement YoY; net EBITDA impact 3-5% after input cost absorption. Ongoing watch on currency and commodity prices.
US tariff policy risk
MediumAnalyst raised concern about 100% tariff on generics from US in 2 years; potential impact on API and formulation sales to US customers and their supply chains.
Formulation segment structural headwinds
LowFormulation revenue -23% YoY; ex-Middle East tender loss, underlying domestic up double-digits. But strategy to address via APIs for addressable markets may continue to pressure formulation mix.
Management
Score 8/10. Clear, specific on numbers. Willing to clarify guidance (40% margin pushed to FY28). Acknowledged delays on injectable facility but reframed as 'on track post-approvals.' Some hedging on exact breakeven and CDMO details (promised follow-ups). Not evasive on tariff risk (honest 'no customer feedback yet'). Q1 delivered guidance (₹257.5 Cr revenue, 26% growth matched). Injectable facility delayed but management reaffirmed commitment. Long-term ₹3,000 Cr vision maintained; phasing extended but targets intact. Historical track record of navigating earlier headwinds (FY26 challenges).
1 · Q2-Q3 FY27
Injectable facility external sales ramp (domestic first, emerging markets H2)
2 · Q2-Q3 FY27
New ANDA approvals (mycophenolate, Tofacitinib) commercialization in Stellon
3 · FY27 end
Second CDMO project commercialization (targeting at least one more deal by year-end)
Key risk: injectable facility and Stellon are at 5% utilization; margin target 40% deferred to FY28, not FY27 end as originally guided.